Shattuck Labs Inc. (STTK)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Shattuck Labs, Inc. (STTK) Discusses Phase I Results for DR3 Blocking Antibody SL-325 and Pipeline Update Transcript
Shattuck Labs, Inc. (STTK) Discusses Phase I Results for DR3 Blocking Antibody SL-325 and Pipeline Update Transcript
What Makes Shattuck Labs, Inc. (STTK) a Strong Momentum Stock: Buy Now?
Does Shattuck Labs, Inc. (STTK) have what it takes to be a top stock pick for momentum investors? Let's find out.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Shattuck Labs, Inc. - STTK
NEW YORK CITY, NY / ACCESSWIRE / November 16, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Shattuck Labs, Inc. ("Shattuck" or the "Company") (NASDAQ:STTK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Shattuck Labs Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Point72 Asset Management LP Point72 Asset Management LP | 1.03M | $3.76M | $6.51M | $2.74M | 72.88% |
| RF Rekah Franca Catalyst Funds Management Pty Ltd. | 17,900 | $115,097 | $114,470.5 | -$626.5 | -0.54% |
| EY Ellen York T. Rowe Price Investment Management Inc. | 9.87M | $62.03M | $64.57M | $2.54M | 4.1% |
 Lansing A. Davis Davis Asset Management LP | 48,276 | $310,414.68 | $313,794 | $3,379.32 | 1.09% |
| RJ Rebecca Judd Pathstone Holdings, LLC | 73,956 | $58,558.36 | $512,411.54 | $453,853.18 | 775.04% |
Shattuck Labs Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Yigal Nochomovitz Citigroup | 746.55 | $3,663.98 | $5,278.09 | $1,614.11 | 44.05% |
Shattuck Labs Inc. (STTK) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Shattuck Labs Inc. ever had a stock split?
Shattuck Labs Inc. Profile
| Biotechnology Industry | Healthcare Sector | Taylor H. Schreiber CEO | NASDAQ (NGS) Exchange | 82024L103 CUSIP |
| US Country | 40 Employees | - Last Dividend | - Last Split | 9 Oct 2020 IPO Date |
Overview
Shattuck Labs, Inc. is a forward-thinking biotechnology company focused on the clinical-stage development of innovative therapeutics. Founded in 2016 and based in Austin, Texas, the company dedicates its research and development efforts to tackling some of the most challenging health issues today, primarily cancer and autoimmune diseases. By leveraging cutting-edge technology and scientific research, Shattuck Labs aims to create treatments that can significantly improve patient outcomes in areas where traditional therapies have fallen short.
Products and Services
- SL-172154
This lead product candidate exemplifies Shattuck Labs' innovative approach to medical treatments. Currently in Phase 1 clinical trials, SL-172154 is being developed for patients with ovarian, fallopian tube, and peritoneal cancers. This pioneering treatment represents the forefront of the company’s commitment to addressing some of the most pressing needs within oncology. By focusing on these specific cancers, Shattuck Labs underscores its dedication to contributing significant advancements in the treatment and understanding of these diseases.
